{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:16:10Z","timestamp":1790162170069,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.ejca.2021.02.021","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T08:17:55Z","timestamp":1616487475000},"page":"297-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway"],"prefix":"10.1016","volume":"148","author":[{"given":"Lili","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1641-6716","authenticated-orcid":false,"given":"Yabin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xieqiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoting","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caili","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghui","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.02.021_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1471-2407-11-85","article-title":"Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases","volume":"11","author":"Chi","year":"2011","journal-title":"BMC Canc"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.021_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.021_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","article-title":"Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort","volume":"48","author":"Si","year":"2012","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.02.021_bib4","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-3168","article-title":"Safety, efficacy and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial","author":"Tang","year":"2020","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2021.02.021_bib5","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jclinpath-2013-202127","article-title":"Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker","volume":"67","author":"Lade-Keller","year":"2014","journal-title":"J Clin Pathol"},{"issue":"5","key":"10.1016\/j.ejca.2021.02.021_bib6","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaad.2014.06.036","article-title":"Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling","volume":"71","author":"Potrony","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2021.02.021_bib7","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/pcmr.12228","article-title":"Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4\/6 inhibitor PD0332991 in melanoma cell lines","volume":"27","author":"Young","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.021_bib8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/CCO.0000000000000159","article-title":"Cell cycle control as a promising target in melanoma","volume":"27","author":"Lee","year":"2015","journal-title":"Curr Opin Oncol"},{"issue":"22","key":"10.1016\/j.ejca.2021.02.021_bib9","doi-asserted-by":"crossref","first-page":"6946","DOI":"10.1158\/1078-0432.CCR-17-0070","article-title":"Frequent genetic aberrations in the CDK4 pathway in acral melanoma indicate the potential for CDK4\/6 inhibitors in targeted therapy","volume":"23","author":"Kong","year":"2017","journal-title":"Clin Canc Res"},{"issue":"21","key":"10.1016\/j.ejca.2021.02.021_bib10","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1158\/1078-0432.CCR-19-0475","article-title":"Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma","volume":"25","author":"Yu","year":"2019","journal-title":"Clin Canc Res"},{"issue":"21","key":"10.1016\/j.ejca.2021.02.021_bib11","doi-asserted-by":"crossref","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver","year":"2015","journal-title":"Clin Canc Res"},{"issue":"4","key":"10.1016\/j.ejca.2021.02.021_bib12","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2021.02.021_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186479","article-title":"Targeting cell cycle in breast cancer: CDK4\/6 Inhibitors","volume":"21","author":"Piezzo","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"15","key":"10.1016\/j.ejca.2021.02.021_bib14","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1002\/cncr.32931","article-title":"Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: resistance mechanisms and novel treatment strategies","volume":"126","author":"Sharifi","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2021.02.021_bib15","doi-asserted-by":"crossref","first-page":"62","DOI":"10.21037\/cco.2018.06.08","article-title":"Palbociclib for treatment of metastatic melanoma with copy number variations of CDK4 pathway: case report","volume":"7","author":"Tang","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ejca.2021.02.021_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Contr Clin Trials"},{"issue":"6127","key":"10.1016\/j.ejca.2021.02.021_bib17","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ejca.2021.02.021_bib18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1535-6108(03)00217-4","article-title":"Cell cycle progression without cyclin E\/CDK2: breaking down the walls of dogma","volume":"4","author":"Gladden","year":"2003","journal-title":"Canc Cell"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.021_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrc.2016.138","article-title":"Cell cycle proteins as promising targets in cancer therapy","volume":"17","author":"Otto","year":"2017","journal-title":"Nat Rev Canc"},{"issue":"5","key":"10.1016\/j.ejca.2021.02.021_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3390\/genes10050331","article-title":"Post-translational modifications of the mini-chromosome maintenance proteins in DNA replication","volume":"10","author":"Li","year":"2019","journal-title":"Genes"},{"issue":"26","key":"10.1016\/j.ejca.2021.02.021_bib21","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMx180043","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"379","author":"Hortobagyi","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.021_bib22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11060-018-2977-3","article-title":"Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma","volume":"140","author":"Taylor","year":"2018","journal-title":"J Neuro Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2021.02.021_bib23","doi-asserted-by":"crossref","first-page":"C550","DOI":"10.1152\/ajpcell.00176.2011","article-title":"Hypoxia. Cross talk between oxygen sensing and the cell cycle machinery","volume":"301","author":"Semenza","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.021_bib24","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/jcb.29361","article-title":"MCM7 silencing promotes cutaneous melanoma cell autophagy and apoptosis by inactivating the AKT1\/mTOR signaling pathway","volume":"121","author":"Yang","year":"2020","journal-title":"J Cell Biochem"},{"issue":"9","key":"10.1016\/j.ejca.2021.02.021_bib25","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejca.2021.02.021_bib26","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Canc Discov"},{"issue":"1","key":"10.1016\/j.ejca.2021.02.021_bib27","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/s41467-019-09711-y","article-title":"LNK suppresses interferon signaling in melanoma","volume":"10","author":"Ding","year":"2019","journal-title":"Nat Commun"},{"issue":"13","key":"10.1016\/j.ejca.2021.02.021_bib28","doi-asserted-by":"crossref","first-page":"E2950","DOI":"10.1073\/pnas.1720431115","article-title":"Cyclin-dependent kinase activity is required for type I interferon production","volume":"115","author":"Cing\u00f6z","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.ejca.2021.02.021_bib29","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1158\/1535-7163.MCT-14-0257","article-title":"The CDK4\/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation","volume":"13","author":"Yadav","year":"2014","journal-title":"Mol Canc Therapeut"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2021.02.021_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9545","article-title":"Phase I-II open label multicenter study of PD0332991 in BRAF V600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib","volume":"37","author":"Louveau","year":"2019","journal-title":"J Clin Oncol"},{"issue":"7686","key":"10.1016\/j.ejca.2021.02.021_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D\u2013CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921001040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:48Z","timestamp":1760733108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921001040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":31,"alternative-id":["S0959804921001040"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.02.021","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}